Bristol-Myers Squibb Company
Immunomodulators
Last updated:
Abstract:
The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
Status:
Grant
Type:
Utility
Filling date:
21 Mar 2017
Issue date:
22 Oct 2019